Chemomab Therapeutics Ltd reported raising $10 Million in an initial SEC Form D filing, from an offering of $10 Million
PUBLIC · CMMBAug 09, 2024
Amount Raised
$10 Million
$10 Million sold, per SEC Form D (first sale Jul 29, 2024)
Round Type
Venture
Tel AvivBiotechnologyHealth CareTherapeutics
Quick answer
Chemomab Therapeutics Ltd raised $10 Million in a funding round, dated July 29, 2024. Chemomab Therapeutics Ltd is based in Tel Aviv, Tel Aviv District, Israel.
How much did Chemomab Therapeutics Ltd raise?
Chemomab Therapeutics Ltd raised $10 Million in a funding round on July 29, 2024.
What does Chemomab Therapeutics Ltd do?
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Where is Chemomab Therapeutics Ltd based and how big is it?
Chemomab Therapeutics Ltd is based in Tel Aviv, Tel Aviv District, Israel. Fundz records about 20 employees.
Who are the decision-makers at Chemomab Therapeutics Ltd?
Fundz holds 1 contact at Chemomab Therapeutics Ltd. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Chemomab Therapeutics Ltd, and when
A new round usually means Chemomab Therapeutics Ltd is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Chemomab Therapeutics Ltd raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Chemomab Therapeutics Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Chemomab Therapeutics Ltd. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Chemomab Therapeutics Ltd
Location
KIRYAT ATIDIM, BUILDING 7
Tel Aviv, Tel Aviv District, Israel
About
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing. For more information on Chemomab, visit chemomab.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Chemomab Therapeutics Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Tel AvivBiotechnologyHealth CareTherapeutics